Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major molecular response rates at week 96. The study compared ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential. First-in-class STAMP ...

U.S. stock markets have witnessed an impressive rally since the beginning of 2023 barring some minor hurdles. Wall Street’s ...

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML). At the ASCO congress in Chicago today, the results ...

Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix ® (asciminib) showing superior major molecular response ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated ...

Novartis announced positive, longer-term results from the pivotal phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 961. The study ...

Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix ® (asciminib) showing superior major molecular response (MMR) ...